Lost: 10kg in 12 weeks on Zafgen obesity drug beloranib
This article was originally published in Scrip
Zafgen reported weight loss of up to 10kg in 12 weeks – about 22lbs total or nearly 2lbs per week – for beloranib-treated patients among the first 19 people enrolled in the company's Phase II clinical trial for the obesity drug.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.